CL2014001055A1 - Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso. - Google Patents

Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso.

Info

Publication number: CL2014001055A1
Authority: CL; Chile
Prior art keywords: tnf; interleukin; binds; vector; nucleic acid
Prior art date: 2011-10-24

Application number

CL2014001055A

Other languages

English (en)

Inventor

Chung-Ming Hsieh

Jennifer Perez

Lorenzo Benatuil

Yuliya Kutskova

John Memmott

Suju Zhong

Lucia Eaton

Margaret Hugunin

Alyssa Brito

Anca Clabbers

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-24

Filing date

2014-04-24

Publication date

2014-08-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47144148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001055(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-04-24 Application filed by Abbvie Inc filed Critical Abbvie Inc

2014-08-18 Publication of CL2014001055A1 publication Critical patent/CL2014001055A1/es

Links

102000013691 Interleukin-17 Human genes 0.000 title 1
108050003558 Interleukin-17 Proteins 0.000 title 1
108060008682 Tumor Necrosis Factor Proteins 0.000 title 1
102000023732 binding proteins Human genes 0.000 title 1
108091008324 binding proteins Proteins 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
102000039446 nucleic acids Human genes 0.000 title 1
108020004707 nucleic acids Proteins 0.000 title 1
150000007523 nucleic acids Chemical class 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
102000003390 tumor necrosis factor Human genes 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Biotechnology (AREA)
Rheumatology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Food Science & Technology (AREA)

CL2014001055A 2011-10-24 2014-04-24 Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso. CL2014001055A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161550619P	2011-10-24	2011-10-24

Publications (1)

Publication Number	Publication Date
CL2014001055A1 true CL2014001055A1 (es)	2014-08-18

Family

ID=47144148

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014001055A CL2014001055A1 (es)	2011-10-24	2014-04-24	Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso.

Country Status (26)

Country	Link
US (2)	US9655964B2 (es)
EP (1)	EP2771361A1 (es)
JP (1)	JP6121432B2 (es)
KR (1)	KR20140084254A (es)
CN (1)	CN104185641A (es)
AR (1)	AR088514A1 (es)
AU (1)	AU2012328917B2 (es)
BR (1)	BR112014009810A2 (es)
CA (1)	CA2853114A1 (es)
CL (1)	CL2014001055A1 (es)
CO (1)	CO7020874A2 (es)
CR (1)	CR20140224A (es)
DO (1)	DOP2014000084A (es)
EC (1)	ECSP14001260A (es)
GT (1)	GT201400077A (es)
HK (1)	HK1200321A1 (es)
IL (1)	IL232207A0 (es)
MX (1)	MX2014004980A (es)
PE (1)	PE20142245A1 (es)
PH (1)	PH12014500903A1 (es)
RS (1)	RS20140202A1 (es)
RU (1)	RU2014121043A (es)
SG (1)	SG11201401796SA (es)
TW (1)	TW201323441A (es)
UY (1)	UY34410A (es)
WO (1)	WO2013063110A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102741288B (zh)	2009-08-29	2015-08-19	Abbvie公司	治疗用dll4结合蛋白
CN105037543B (zh)	2010-03-02	2020-11-03	Abbvie 公司	治疗性dll4结合蛋白
MX2012013490A (es)	2010-05-20	2013-01-29	Ablynx Nv	Materiales biologicos relacionados con her3.
KR20130100118A (ko)	2010-08-03	2013-09-09	아비에 인코포레이티드	이원 가변 도메인 면역글로불린 및 이의 용도
UY33679A (es)	2010-10-22	2012-03-30	Esbatech	Anticuerpos estables y solubles
AR084210A1 (es) *	2010-12-08	2013-05-02	Abbott Lab	PROTEINAS DE UNION AL TNF-a
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
UY34409A (es)	2011-10-24	2013-05-31	Abbvie Inc	Inmunoenlazadores dirigidos contra el tnf
US9217042B2 (en) *	2012-10-23	2015-12-22	Abbott Cardiovascular Systems Inc.	Method of reducing MACE in diabetic patients subsequent to stent placement
WO2014071074A2 (en)	2012-11-01	2014-05-08	Abbvie Inc.	Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
WO2014144299A2 (en) *	2013-03-15	2014-09-18	Abbvie Inc.	DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα
HRP20201432T1 (hr) *	2013-11-18	2020-12-11	Shanghai Hengrui Pharmaceutical Co., Ltd.	Il-17a sredstvo za vezivanje i njegove uporabe
AU2015240595B2 (en)	2014-04-03	2020-02-27	Igm Biosciences, Inc.	Modified J-chain
WO2015191760A2 (en) *	2014-06-10	2015-12-17	Abbvie, Inc.	Compositions and methods for treating rheumatoid arthritis
WO2015191783A2 (en)	2014-06-10	2015-12-17	Abbvie Inc.	Biomarkers for inflammatory disease and methods of using same
KR102427097B1 (ko) *	2014-08-26	2022-08-01	암젠 케이-에이, 인크.	항-tnf-알파 항체 요법을 받은 건선 환자의 치료 방법
EP3189153B1 (en)	2014-09-03	2021-06-16	Boehringer Ingelheim International GmbH	Compound targeting il-23a and tnf-alpha and uses thereof
AR102417A1 (es)	2014-11-05	2017-03-01	Lilly Co Eli	Anticuerpos biespecíficos anti-tnf- / anti-il-23
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
GB201500463D0 (en) *	2015-01-12	2015-02-25	Cresendo Biolog Ltd	Therapeutic molecules
US10689449B2 (en)	2015-01-20	2020-06-23	Igm Biosciences, Inc.	Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
AU2016329197B2 (en)	2015-09-30	2021-01-21	Igm Biosciences, Inc.	Binding molecules with modified J-chain
WO2017059387A1 (en)	2015-09-30	2017-04-06	Igm Biosciences, Inc.	Binding molecules with modified j-chain
AU2016335017A1 (en) *	2015-10-05	2018-03-29	Galapagos Nv	Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitis
EP3389714A4 (en)	2015-12-14	2019-11-13	MacroGenics, Inc.	BIS-SPECIFIC MOLECULES WITH IMMUNE REACTIVITY WITH PD-1 AND CTLA-4 AND METHOD OF USE THEREOF
GB201522394D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
GB201522391D0 (en) *	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibody molecules
EP3408293A4 (en) *	2016-01-28	2019-09-11	Janssen Biotech, Inc.	BIS-SPECIFIC ANTI-TNF-ALPHA / IL-17A ANTIBODIES AND ANTI-TNF-ALPHA ANTIBODIES AND METHODS FOR THEIR USE
RU2680011C2 (ru) *	2016-04-29	2019-02-14	Закрытое Акционерное Общество "Биокад"	Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
HRP20210924T1 (hr)	2016-06-02	2021-09-03	Abbvie Inc.	Agonist glukokortikoidnog receptora i njegovi imunokonjugati
WO2018089300A1 (en) *	2016-11-10	2018-05-17	Merck Sharp & Dohme Corp.	Ilt3 ligand
EP3684801A1 (en) *	2017-09-22	2020-07-29	H. Hoffnabb-La Roche Ag	Multivalent mono- or bispecific recombinant antibodies for analytic purpose
SI3658192T1 (sl)	2017-12-01	2021-08-31	Abbvie Inc.	Agonist glukokortikoidnega receptorja in njegovi imunokonjugati
JP7525499B2 (ja)	2019-01-31	2024-07-30	ヌマブセラピューティクスアクチェンゲゼルシャフト	ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
AU2020231509A1 (en) *	2019-03-04	2021-08-19	Amgen Inc.	In vivo reversibility of high molecular weight species
EP3980448A4 (en) *	2019-06-04	2023-06-28	Academia Sinica	Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
JP7735291B2 (ja)	2020-02-21	2025-09-08	エーアールエスファーマシューティカルズ、インコーポレイテッド	ネクチン－４抗体コンジュゲートおよびその使用
BR112022022986A2 (pt)	2020-05-13	2023-01-17	Disc Medicine Inc	Anticorpos anti-hemojuvelina (hjv) para tratar mielofibrose
AU2021300362A1 (en)	2020-07-01	2023-02-23	ARS Pharmaceuticals, Inc.	Anti-ASGR1 antibody conjugates and uses thereof
CN112375149B (zh) *	2020-10-30	2023-04-18	沣潮医药科技（上海）有限公司	Ace2免疫融合蛋白及其应用
CA3235096A1 (en)	2021-11-17	2023-05-25	Disc Medicine, Inc.	Methods for treating anemia of kidney disease
TW202525846A (zh)	2023-08-25	2025-07-01	美商普羅特歐拉吉克適美國公司	抗ｉｌ—１３多特異性抗體構築體及其用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
DE3631229A1 (de) *	1986-09-13	1988-03-24	Basf Ag	Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5006309A (en)	1988-04-22	1991-04-09	Abbott Laboratories	Immunoassay device with liquid transfer between wells by washing
US5089424A (en)	1988-06-14	1992-02-18	Abbott Laboratories	Method and apparatus for heterogeneous chemiluminescence assay
SE462454B (sv)	1988-11-10	1990-06-25	Pharmacia Ab	Maetyta foer anvaendning i biosensorer
FI903489A7 (fi)	1988-11-11	1990-07-10	Medical Res Council	Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5063081A (en)	1988-11-14	1991-11-05	I-Stat Corporation	Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
CA2048302A1 (en)	1990-08-15	1992-02-16	Victoria P. Meucci	Solubilization reagent for biological test samples
US5135875A (en)	1990-08-15	1992-08-04	Abbott Laboratories	Protein precipitation reagent
CA2069530A1 (en)	1991-06-03	1992-12-04	Cass J. Grandone	Reagent pack for immunoassays
DE69328622T2 (de)	1992-03-30	2001-02-08	Abbott Laboratories, Abbott Park	Reagenzien und verfahren zum nachweis und zur quantifizierung von thyroxin in flüssigen proben
US6309636B1 (en) *	1995-09-14	2001-10-30	Cancer Research Institute Of Contra Costa	Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en)	1995-04-14	2000-02-01	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
US6127977A (en)	1996-11-08	2000-10-03	Cohen; Nathan	Microstrip patch antenna with fractal structure
CN103275221B (zh)	1996-02-09	2016-08-17	艾伯维生物技术有限公司	结合人TNFα的人抗体
NZ516848A (en)	1997-06-20	2004-03-26	Ciphergen Biosystems Inc	Retentate chromatography apparatus with applications in biology and medicine
ATE340870T1 (de)	1998-04-03	2006-10-15	Compound Therapeutics Inc	Adressierbare protein arrays
US6406921B1 (en)	1998-07-14	2002-06-18	Zyomyx, Incorporated	Protein arrays for high-throughput screening
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
AU4025300A (en)	1999-03-24	2000-10-09	Packard Bioscience Company	Continuous porous matrix arrays
US6914128B1 (en)	1999-03-25	2005-07-05	Abbott Gmbh & Co. Kg	Human antibodies that bind human IL-12 and methods for producing
KR20020093029A (ko)	2000-04-11	2002-12-12	제넨테크, 인크.	다가 항체 및 그의 용도
SK1152003A3 (en)	2000-06-29	2003-07-01	Abbott Lab	Dual specificity antibodies and methods of making and using
US7419821B2 (en)	2002-03-05	2008-09-02	I-Stat Corporation	Apparatus and methods for analyte measurement and immunoassay
CA2872136C (en)	2002-07-18	2017-06-20	Merus B.V.	Recombinant production of mixtures of antibodies
US20040018577A1 (en)	2002-07-29	2004-01-29	Emerson Campbell John Lewis	Multiple hybrid immunoassay
ATE472556T1 (de)	2002-12-02	2010-07-15	Amgen Fremont Inc	Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
CN1942588B (zh)	2003-03-05	2013-06-12	海洋酶公司	可溶性透明质酸酶糖蛋白(sHASEGP)、制备它们的方法、它们的用途和包含它们的药物组合物
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2005014650A2 (en)	2003-06-16	2005-02-17	Celltech R & D, Inc.	Antibodies specific for sclerostin and methods for increasing bone mineralization
EP1660534A2 (en)	2003-08-22	2006-05-31	MedImmune, Inc.	Humanization of antibodies
US7723099B2 (en)	2003-09-10	2010-05-25	Abbott Point Of Care Inc.	Immunoassay device with immuno-reference electrode
US7682833B2 (en)	2003-09-10	2010-03-23	Abbott Point Of Care Inc.	Immunoassay device with improved sample closure
BRPI0511448A (pt)	2004-07-06	2007-12-26	Bioren Inc	anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
US7883855B2 (en)	2006-07-21	2011-02-08	Abbott Laboratories	Immunosuppressant drug extraction reagent for immunoassays
EP2460828A3 (en)	2006-11-10	2012-08-08	UCB Pharma, S.A.	Antibodies and diagnostics
EP2097450A2 (en)	2006-11-10	2009-09-09	Amgen Inc.	Antibody-based diagnostics and therapeutics
BRPI0809026A2 (pt)	2007-03-20	2014-09-23	Lilly Co Eli	Anticorpos antiesclerotina
US7906293B2 (en)	2007-04-09	2011-03-15	Abbott Laboratories	Acridinium phenyl esters useful in the analysis of biological
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
TWI478937B (zh)	2008-01-15	2015-04-01	Abbvie Inc	改良之哺乳動物表現載體及其用途
RU2010153580A (ru) *	2008-06-03	2012-07-20	Эбботт Лэборетриз (Us)	Иммуноглобулины с двумя вариабельными доменами и их применение
MX2011009362A (es)	2009-03-05	2011-09-26	Abbott Lab	Proteinas de union a il-17.
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
SG184473A1 (en)	2010-04-07	2012-11-29	Abbvie Inc	Tnf-alpha binding proteins
KR20130100118A (ko)	2010-08-03	2013-09-09	아비에 인코포레이티드	이원 가변 도메인 면역글로불린 및 이의 용도
AR084210A1 (es)	2010-12-08	2013-05-02	Abbott Lab	PROTEINAS DE UNION AL TNF-a
CA2853258A1 (en)	2011-10-24	2013-05-02	Abbvie Inc.	Immunobinders directed against sclerostin
UY34409A (es)	2011-10-24	2013-05-31	Abbvie Inc	Inmunoenlazadores dirigidos contra el tnf

2012
- 2012-10-24 SG SG11201401796SA patent/SG11201401796SA/en unknown
- 2012-10-24 AR ARP120103979A patent/AR088514A1/es unknown
- 2012-10-24 RU RU2014121043/10A patent/RU2014121043A/ru not_active Application Discontinuation
- 2012-10-24 US US13/659,666 patent/US9655964B2/en active Active
- 2012-10-24 MX MX2014004980A patent/MX2014004980A/es unknown
- 2012-10-24 BR BR112014009810A patent/BR112014009810A2/pt not_active IP Right Cessation
- 2012-10-24 RS RS20140202A patent/RS20140202A1/en unknown
- 2012-10-24 AU AU2012328917A patent/AU2012328917B2/en not_active Ceased
- 2012-10-24 HK HK15100713.9A patent/HK1200321A1/xx unknown
- 2012-10-24 KR KR1020147013797A patent/KR20140084254A/ko not_active Withdrawn
- 2012-10-24 CA CA2853114A patent/CA2853114A1/en not_active Abandoned
- 2012-10-24 PE PE2014000606A patent/PE20142245A1/es not_active Application Discontinuation
- 2012-10-24 UY UY0001034410A patent/UY34410A/es not_active Application Discontinuation
- 2012-10-24 JP JP2014538926A patent/JP6121432B2/ja active Active
- 2012-10-24 WO PCT/US2012/061686 patent/WO2013063110A1/en active Application Filing
- 2012-10-24 PH PH1/2014/500903A patent/PH12014500903A1/en unknown
- 2012-10-24 EP EP12783474.5A patent/EP2771361A1/en not_active Withdrawn
- 2012-10-24 CN CN201280064228.6A patent/CN104185641A/zh active Pending
- 2012-10-24 TW TW101139328A patent/TW201323441A/zh unknown
2013
- 2013-11-18 US US14/082,502 patent/US20140079705A1/en not_active Abandoned
2014
- 2014-04-23 IL IL232207A patent/IL232207A0/en unknown
- 2014-04-24 CL CL2014001055A patent/CL2014001055A1/es unknown
- 2014-04-24 DO DO2014000084A patent/DOP2014000084A/es unknown
- 2014-04-24 GT GT201400077A patent/GT201400077A/es unknown
- 2014-05-14 CR CR20140224A patent/CR20140224A/es unknown
- 2014-05-19 EC ECIEPI20141260A patent/ECSP14001260A/es unknown
- 2014-05-22 CO CO14110752A patent/CO7020874A2/es unknown

Also Published As

Publication number	Publication date
AR088514A1 (es)	2014-06-18
US20140161804A1 (en)	2014-06-12
PE20142245A1 (es)	2015-01-22
RU2014121043A (ru)	2015-12-10
KR20140084254A (ko)	2014-07-04
ECSP14001260A (es)	2015-07-31
AU2012328917B2 (en)	2017-05-25
SG11201401796SA (en)	2014-10-30
JP6121432B2 (ja)	2017-04-26
CO7020874A2 (es)	2014-08-11
US9655964B2 (en)	2017-05-23
BR112014009810A2 (pt)	2017-04-25
AU2012328917A1 (en)	2014-05-22
US20140079705A1 (en)	2014-03-20
IL232207A0 (en)	2014-06-30
TW201323441A (zh)	2013-06-16
CR20140224A (es)	2014-09-03
RS20140202A1 (en)	2014-10-31
DOP2014000084A (es)	2014-09-15
GT201400077A (es)	2014-12-23
HK1200321A1 (en)	2015-08-07
CN104185641A (zh)	2014-12-03
EP2771361A1 (en)	2014-09-03
WO2013063110A1 (en)	2013-05-02
CA2853114A1 (en)	2013-05-02
MX2014004980A (es)	2014-09-11
PH12014500903A1 (en)	2014-06-09
UY34410A (es)	2013-05-31
JP2015502145A (ja)	2015-01-22

Publication	Publication Date	Title
CL2014001055A1 (es)	2014-08-18	Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso.
CL2014001054A1 (es)	2014-09-05	Proteina de enlace que se une al factor de necrosis tumoral alfa (tnf-alfa); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; su uso para tratar un trastorno asociado a tnf-alfa; y metodo para determinar la presencia de tnf-alfa en una muestra.
CL2013000566A1 (es)	2014-01-24	Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2013001625A1 (es)	2014-02-21	Proteina de union que se une especificamente a tnf-alfa; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad o trastorno asociado a tnf-alfa.
CL2012003610A1 (es)	2013-05-17	Proteina de union multivalente y multiespecífica que se une al factor de necrosis tumoral (tnf) y al inductor de apoptosis debil relacionado con el factor de necrosis tumoral (tweak); conjugado de union de dicha proteína; acido nucleico que la codifica; vector y célula que comprenden dicho acido nucleico; metodo para producir dicha proteína; composicion farmacéutica que comprende dicha proteína
CL2009000459A1 (es)	2010-12-10	Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
CL2013001831A1 (es)	2013-11-08	Proteina de enlace multivalente y multiespecifica que une a il-1 alfa y beta; conjugado que la comprende; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y sus usos.
CL2013000074A1 (es)	2013-12-06	Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos.
CL2014000631A1 (es)	2014-09-26	Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
PH12020551907A1 (en)	2021-06-14	Antagonizing cd73 antibody
CL2013003336A1 (es)	2014-06-06	Anticuerpo anti-cgrp humano; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica y diagnostica que lo comprende; y su uso terapéutico
CL2014000699A1 (es)	2014-09-12	Proteina de union al antigeno cd27l; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; composicion que la comprende; su uso para tratar cancer, trastornos autoinmunitarios o inflamatorios; y metodo para elaborar un conjugado anticuerpo cd27l-farmaco.
CL2013001210A1 (es)	2013-11-08	Proteina de union multivalente que une ya sea a tnf y pge2 o vegf y dll4; conjugado que la comprende; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y sus usos.
CL2012002783A1 (es)	2013-07-12	Proteinas de unión humanizada que se une al factor de necrosis tumoral alfa humano (tnf-alfa); composicion para liberar una proteina que se une a tnf-alfa; construccionde una proteina que puede unirse al tnf-alfa; acido nucleico, vector y celula huesped que comprenden dicha construccion.
CL2013000369A1 (es)	2014-08-08	Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2010001425A1 (es)	2011-04-08	Proteina de union que comprende una cadena polipeptidica capaz de unir un par de antigenos; acido nucleico aislado que codifica dicha proteina de union; vector y celula huesped; metodo para producir proteina de union; composicion farmaceutica que comprende dicha proteina.
CL2013001279A1 (es)	2014-03-07	Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
EA201492101A1 (ru)	2015-04-30	Антитела против fcrn
CL2013001403A1 (es)	2014-08-08	Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
MX2015008446A (es)	2016-10-26	Composiciones de proteinas de union multivalentes.
CL2012003093A1 (es)	2013-03-22	Anticuerpo aislado multivalente que tiene al menos dos dominios de union a receptores para dos diferentes sitios de union de un receptor diana lrp6 que inhiben una via canonica de transduccion de señal wnt; anticuerpo aislado biparatopico que une lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; metodo de obtencion de dicho anticuerpo; y su uso para tratar cancer.
CL2011002567A1 (es)	2012-02-24	Anticuerpo antifactor de necrosis tumoral alfa (tnf-a) o fragmento de union del mismo; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno inmune.
MX374682B (es)	2025-03-06	Moléculas de unión a 4-1bb.
CL2008002444A1 (es)	2009-09-04	Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
CL2012002662A1 (es)	2013-01-25	Anticuerpos bivalentes biespecificos anti-veg y un segundo sitio de unión a antígeno que se une específicamente a ang-2 humana; composicion farmacéutica que comprende dicho anticuerpo; método de tratamiento de un paciente que sufre cancer; acido nucleico codificante de dicho anticuerpo, vector de expresión y célula huesped que contiene dicho ácido nucleico.